Epistem’s Biomarker Focus in the US
Epistem Plc will open a US office based in Boston, MA to increase its presence in the all important North American Market. The US office (‘Epistem Inc’) will support the commercialisation of the recently launched proprietary GenetRxTM biomarker platform in oncology.
Epistem’s biomarker collaborations in North America will focus on preclinical and clinical oncology drug development providing a means of translating drug effect in specific oncology pathways such as Hedgehog, WNT, Notch, Beta Catenin, PI3 kinase and androgen signalling as well as providing an ideal platform for evaluating therapies aimed at specific RNA targets. The Biomarker Laboratory services will be delivered within a regulatory framework to comply with Good Clinical Laboratory Practice (GcLP).
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Horizon and Boehringer Ingelheim enter oncology research service collaboration
Hesperion announces the opening of its Russian Moscow Office

Takara Bio and Eppendorf cooperate - Automation of Takara Bio’s Chemistries on Eppendorf’s Automated Pipetting Systems for Significantly Higher Efficiency
New genetic links to MS also play roles in other autoimmune diseases

Dust mite allergens trigger inflammatory responses - Dust mite allergens activate the pulmonary immune system, thereby triggering allergies
